DNLI Stock: Price, Earnings History and SEC Filings
Denali Therapeutics Inc. (DNLI) last traded at $18.94, down 1.97% on the latest session and down 8.4% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.68 against an analyst estimate of $-0.72, a beat of 5.6%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
DNLI earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 6, 2026 | $-0.68 | $-0.72 | +5.56% |
| Mar 2026 | May 7, 2026 | $-0.69 | $-0.73 | +5.48% |
| Dec 2025 | Feb 26, 2026 | $-0.73 | $-0.75 | +2.67% |
| Sep 2025 | Nov 6, 2025 | $-0.74 | $-0.76 | +2.63% |
DNLI beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
How DNLI reacts to earnings
Across its last 8 earnings releases, DNLI moved 3.1% on average the next session, in either direction. It rose after 4 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-06 | After close | +0.40% |
| 2026-05-07 | After close | -0.46% |
| 2026-02-26 | After close | -1.12% |
| 2025-11-06 | After close | +4.23% |
| 2025-08-11 | After close | -5.03% |
| 2025-05-06 | After close | +2.51% |
| 2025-02-27 | After close | -10.97% |
| 2024-11-06 | After close | +0.17% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
DNLI financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $0 | -$513M | -$422M | – | $-2.97 |
| 2024 | $0 | -$423M | -$364M | – | $-2.57 |
| 2023 | $331M | -$145M | -$371M | -43.9% | $-1.06 |
| 2022 | $105M | -$326M | -$263M | -310.3% | $-2.60 |
| 2021 | $49M | -$291M | -$220M | -597.2% | $-2.39 |
| 2020 | $336M | $71M | $413M | 21.2% | $0.63 |
| 2019 | $26M | -$198M | -$169M | -750.8% | $-2.07 |
| 2018 | $129M | -$36M | $47M | -28.1% | $-0.39 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for DNLI
- 10-Q · Aug 6, 2026
- 8-K · Aug 6, 2026Results of operations, Financial statements and exhibits
- 8-K · Jul 28, 2026Acquisition or disposal completed, Financial statements and exhibits
- 8-K · Jun 18, 2026Material agreement, Regulation FD disclosure, Financial statements and exhibits
- 8-K · Jun 4, 2026Shareholder vote, Financial statements and exhibits
- 8-K · May 22, 2026Regulation FD disclosure
- 10-Q · May 7, 2026
- 8-K · May 7, 2026Results of operations, Financial statements and exhibits
- DEF 14A · Apr 21, 2026
- 8-K · Apr 3, 2026Agreement terminated, Financial statements and exhibits
Insider filing activity
DNLI insiders filed 5 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
DNLI news
- Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology ProductOct 30, 2026 · finance.yahoo.com
- Denali Therapeutics to Report Third Quarter 2026 Financial Results and Business Highlights on November 3, 2026Oct 22, 2026 · finance.yahoo.com
About Denali Therapeutics Inc.
Denali Therapeutics Inc. (DNLI) is a US-listed public company on Nasdaq. The SEC classifies its business as Biological Products (no Diagnostic Substances). It is incorporated in DE. Its fiscal year ends in December.